Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05535244 |
|---|---|
| Brief Title: | A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2) |
| First Submitted : | August 24, 2022 |
| First Submitted that Met QC Criteria : | September 8, 2022 |
| First Posted : | September 10, 2022 |
| Last Update Submitted that Met QC Criteria : | April 30, 2024 |
| Last Update Posted : | May 1, 2024 |